When the Food and Drug Administration in January granted marketing approval to a second transcatheter aortic valve replacement system for inoperable patients with aortic stenosis, the CoreValve...
Dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been approved for the treatment of type 2 diabetes with a requirement that the manufacturer conduct postmarketing studies that address...
UPDATED Jan. 4, 2014
The federally funded program to produce a set of U.S. guidelines for hypertension management, a process more than 5 years in the making, came to an unusual end on...
DALLAS – High-potency statin therapy given post acute coronary syndrome did not raise serum creatinine or cause more risk of acute kidney injury than low-potency statin regimens did in a new analysis...
DALLAS – Elderly patients who started treatment with an antipsychotic drug had a substantially increased risk for a major adverse cardiovascular disease event, especially during the first month on...
The group of experts who had constituted the JNC 8 panel, a team assembled in 2008 by the National Heart, Lung, and Blood Institute to update official U.S. hypertension management guidelines, set the...
DALLAS – Rosuvastatin appears to reduce the risk of acute myocardial infarction in patients with ischemic heart failure, according to a meta-analysis of two landmark statin trials.
This finding is...
CHICAGO – Consumption of an energy drink containing caffeine and taurine slightly, but significantly, altered left ventricular contractility in healthy volunteers, while consuming the same amount of...
An abrupt and unexpected increase in pump thrombosis has occurred since March 2011 in patients with advanced heart failure who received the HeartMate II left ventricular assist device, according to a...